CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Moderate Buy” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average recommendation of “Moderate Buy” from the seventeen brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $67.9412.

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Citizens Jmp reiterated a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Finally, Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors raised its position in CRISPR Therapeutics by 4.3% in the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock worth $309,016,000 after purchasing an additional 243,487 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 2,249,223 shares of the company’s stock valued at $117,971,000 after buying an additional 108,053 shares during the period. Norges Bank acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $25,706,000. Northwestern Mutual Wealth Management Co. raised its position in shares of CRISPR Therapeutics by 2,346.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,305 shares of the company’s stock worth $12,077,000 after acquiring an additional 220,892 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock worth $8,073,000 after acquiring an additional 8,200 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $56.56 on Monday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. The stock’s 50 day moving average is $53.08 and its two-hundred day moving average is $52.77. The company has a market capitalization of $5.47 billion, a price-to-earnings ratio of -11.88 and a beta of 1.76. CRISPR Therapeutics has a 1-year low of $44.12 and a 1-year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The company had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. Equities analysts forecast that CRISPR Therapeutics will post -4.47 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.